Trelegy sales were up 62% AER, 58% CER to £194 million with strong growth in all regions. In the US, sales grew 65% AER, 60% CER, reflecting continued
market share growth. In Europe, sales grew 64% AER, 59% CER and in International sales grew 38% AER, 46% CER.
Relvar/Breo sales were up 2% AER, 2% CER to
£242 million in the quarter. In the US, Relvar/Breo declined 11% AER, 12% CER, reflecting competitive pricing pressures and the impact of generic Advair on the US ICS/LABA market. In Europe and International,
Relvar/Breo continued to grow, up 11% AER, 9% CER and 8% AER, 12% CER, respectively.
HIV
HIV sales were £1,185 million, down 2% AER, 3% CER in the quarter. The dolutegravir franchise declined 1% AER, 2% CER, delivering sales of
£1,140 million. The remaining portfolio, with sales of £45 million and 4% of total HIV sales, declined 27% AER, 32% CER and reduced the overall growth of total HIV by one percentage point.
Sales of dolutegravir products were £1,140 million in the quarter. Sales were impacted by customer destocking following the customer stockbuilding in Q1 2020
due to COVID-19, mainly on Tivicay and Triumeq. Tivicay delivered sales of £373 million and declined 9% AER, 10% CER. Triumeq delivered sales of £586 million
and declined 9% AER, 11% CER. The two-drug regimens, Juluca and Dovato delivered sales of £181 million in the quarter, with combined growth more than offsetting the decline of the
three-drug regimen Triumeq.
In the US, dolutegravir sales grew 1% AER, but declined 2% CER and in Europe sales declined 4% AER, 5% CER impacted by customer
destocking following the customer stockbuilding in Q1 2020 due to COVID-19. Following recent launches of Dovato, combined sales of the two-drug regimens were
£139 million in the US and £38 million in Europe, with growth more than offsetting the decline in Triumeq. International was flat at AER, but grew 4% CER, driven by Tivicay.
Oncology
Sales of Zejula, the PARP inhibitor asset acquired
from Tesaro in Q1 2019 were £77 million in the quarter, up 35% AER, 32% CER. Sales comprised £47 million in the US and £30 million in Europe.
Immuno-inflammation
Sales of Benlysta in the quarter were up
18% AER, 15% CER to £177 million, including sales of the sub-cutaneous formulation of £89 million. In the US, Benlysta grew 16% AER, 14% CER to £153 million.
Established Pharmaceuticals
Sales of Established Pharmaceuticals in
the quarter were £1,780 million, down 17% AER, 17% CER.
Established Respiratory products declined 12% AER, 12% CER to £805 million. This
reflected the impact of generic albuterol substitutes on Ventolin in the US, the impact of COVID-19 pandemic related destocking in Europe and allergy market contraction in Japan. In the US, sales of
Advair/Seretide grew 36% AER, 34% CER to £143 million, reflecting a spike in the ICS/LABA class during April and May. In Europe and International, Seretide sales were down 12% AER, 13% CER and 7% AER, 6% CER, respectively,
impacted by generic competition in Europe, COVID-19 related destocking.
The remainder of the Established Pharmaceuticals
portfolio declined 20% AER, 20% CER to £975 million on lower demand for Dermatology products and Antibiotics during the COVID-19 pandemic period, the impact of government mandated changes increasing
the use of generics in China, and comparison with a strong Q2 2019, which included a European Relenza contract.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q2 Results summary
|
|
|
|
Total and Adjusted results
|
|
|
|
Quarterly performance
|
|
|
|
YTD performance
|
|
|
|
Financial information
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13
|